Beta-blockers
Authors:
J. Ďuricová; M. Grundmann
Authors place of work:
Fakulta zdravotnických studií Ostravské univerzity, FN Ostrava, Ústav klinické farmakologie
Published in the journal:
Čes. slov. Farm., 2009; 58, 60-66
Category:
Review Articles
Summary
Beta-adrenergic blockers rank among the principal drugs in the treatment of cardiovascular diseases. Their common mechanism of action is based on the ß-adrenergic receptor blockade. However, differences in pharmacokinetic and pharmacodynamic properties exist between the individual agents in the beta-blocker class, and these differences may be of clinical relevance. In addition, responses to beta-blockers are variable among patients. Genetic plymorphism in drug-metabolizing enzymes, including cytochrome P450 2D6, has been demonstrated to contribute to the variability of several beta-blockers. The understanding of beta-blocker properties and their differences is thus important for their proper clinical use.
Key words:
beta-blockers – pharmacokinetics – pharmacodynamics – P450 2D6
Zdroje
1. Reiter M. J.: Prog Cardiovasc Dis., 2004; 47, 11–33.
2. López–Sendón J., Swedberg K., McMurray J. et al.: Eur Heart J., 2004; 25, 1341–1362.
3. O’Rourke S. T.: Am J Pharm Educ., 2007; 71, 1–6.
4. Bristow M. R.: Circulation, 2000; 101, 558–569.
5. Vítovec J., Špinar J.: Interní Med., 2008; 10, 126–128.
6. Cruickshank J. M.: Circulation., 1990; 82, 60–65.
7. Andrus M. R., Loyed J. V.: Drugs Aging., 2008; 25, 131–144.
8. Prisant L. M.: J Clin Pharmacol., 2008; 48, 225–239.
9. Souček M.: Interní Med., 2008; 2, 58–61.
10. Keating G. M., Jarvis B.: Drugs, 2003; 63, 1697–1741.
11. McDevitt D. G.: Eur Heart J., 1987; 8, 9–14.
12. Riddell J. G., Harron D. W. G., Shanks R. G.: Clin Pharmacokinet., 1987; 12, 305–320.
14. Mehvar R., Brocks D. R.: J Pharm Pharm Sci., 2001; 4, 185–200.
15. Fox K., García M. A., Ardissino D. et al.: Eur Heart J., 2006; 27, 1341–1381.
16. Bassand J. P., Hamm C. H. W., Ardissino D. et al.: Eur Heart J., 2007; 28, 1598–1660.
17. Bělohlávek J, Aschermann M.: Cor Vasa, 2008; 50, 1S7–1S23.
18. Janoušek S.: Interv Akut Kardiol., 2004; 3, 189–191.
19. van de Werf F., Bax J., Betriu A. et al.: Eur Heart J., 2008; 29, 2909–2945.
20. Gourine A., Bondar S. I., Spyer K. M. et al.: Circ Res., 2008; 102, 633–636.
21. Špinar J., Hradec J., Meluzín J. et al.: Cor Vasa, 2007; 49, 5–34.
22. Prakash A., Markham A.: Drugs, 2000; 60, 647–678.
23. Dahlöf B., Sever P. S., Poulter N. R. et al.: Lancet, 2005; 366, 895–906.
24. Dahlöf B., Devereux R. B., Kjeldsen S. E. et al.: Lancet, 2002; 359, 1004–1010.
25. Grundmann M., Kacířová I.: Postgraduální medicína., 2007; 9, 652–660.
26. Widimský J., Cífková R., Špinar J. et al.: Cor Vasa., 2008; 50, 5–22.
27. Zipes D. P., Camm A. J., Borggrefe M. et al.: Europace., 2006; 8, 746–837.
28. Blomström–Lundqvist C, Sheinman MM, Aliot EM a kol. J Am Coll Cardiol., 2003; 42: 1493–1531.
29. Anzenbacher P., Anzenbacherová E.: CMLS Cell Mol Life Sci., 2001; 58, 737–747.
30. Mičuda S., Martínková J., Chládek J. et al.: Remedia., 1998; 8, 226–236.
31. Bernard S., Neville K. A., Nguyen A. T. et al.: Clinical Implications. Oncologist., 2006; 11, 126–135.
32. Buzková H., Pechandová K., Slanař O. et al.: Prague Med Rep., 2006; 107, 383–393.
33. Volotinen M., Turpeinen M., Tolonen A. et al.: Drug Metab Dispos., 2007; 35, 1135–1141.
34. Lewis R. V., Lennard M. S., Jackson P. R. et al.: Br. J. Clin. Pharmacol., 1985; 19, 329–333.
35. Lennard M. S., Lewis R. V., Brawn L. A.: Br. J. Clin. Pharmacol., 1989; 27, 429–434.
36. Nieminen T., Uusitalo H., Mäenpää J. et al.: Eur. J. Clin. Pharmacol., 2005; 61, 811–819.
37. Zhou H. H., Wood A. J. J.: Clin. Pharmacol. Ther., 1995; 57, 518–524.
38. Ishida K., Taira S., Morishita H. et al.: Bil. Pharm. Bull., 2008; 31, 1297–1300.
39. Honda M., Nozawa T., Igarashi N. et al.: Biol. Pharm. Bull., 2005; 28, 1476–1479.
40. Takekuma Y., Takenaka T., Kiyokawa M. et al.: Biol. Pharm. Bull., 2007; 30, 537–542.
41. Graff D. W., Williamson K. M., Pieper J. A. et al.: J. Clin. Pharmacol., 2001; 41, 97–106.
42. Lefebvre J., Poirier L., Poirier P. et al.: Br. J. Clin. Pharmacol., 2006; 63, 575–582.
43. Beresford R., Heel R. C.: Drugs., 1986; 31, 6–28.
44. Frishman W. H., Tepper D., Lazar E. J. et al.: J. Clin. Pharmacol., 1990; 30, 686–692.
45. de Groot M. J., Ackland M. J., Horne V. A. et al.: J. Med. Chem., 1999; 42, 4062–4070.
46. Zateyshchikov D. A., Minushkina L. O., Brovkin A. N. et al.: Fund. Clin. Pharmacol., 2007; 21, 437–443.
47. RegĆrdh C. G., Johnsson G.: Clin. Pharmacokinet., 1980; 5, 557–569.
48. Peřinová I., Ďuricová J., Brozmanová H., Kacířová I., Grundmann M.: Čes. a slov. Farm., 2008; 57, 254–259.
49. Cerqueira P. M., Cesarino E. J., Mateus F. H. et al.: Chirality., 1999; 11, 591–597.
50. Ismail R., Teh L. K.: J Clin Pharm Ther., 2006; 31, 99–109.
51. Koytchev R., Alken R. G., Vlahov V. et al.: Eur J Clin Pharmacol., 1998; 54, 469–474.
42. Seeringer A., Brockmöller J., Bauer S. et al.: Eur J Clin Pharmacol., 2008; 64, 883–888.
52. Kirchheiner J., Heesch C., Bauer S. et al.: Clin Pharmacol Ther., 2004; 76, 302–312.
53. Goryachkina K., Burbello A., Boldueva S. et al.: Eur J Clin Pharmacol 2008; 64, 1163–1173.
54. Bijl M. J., Visser L. E., van Schaik R. H. N. et al.: Clin Pharmacol Ther., 2009; 85, 45–50.
55. Wuttke H., Rau T., Heide R. et al.: Clin Pharmacol Ther., 2002; 72, 429–437.
56. Fux R., Mörike K., Pröhmer A. M. T. et al.: Clin Pharmacol Ther., 2005; 78, 378–387.
57. Zineh I., Beitelshees A. L., Gaedigk A. et al.: Clin Pharmacol Ther., 2004; 76, 536–544.
Štítky
Pharmacy Clinical pharmacologyČlánok vyšiel v časopise
Czech and Slovak Pharmacy
2009 Číslo 2
Najčítanejšie v tomto čísle
- Beta-blockers
- On the terms pharmaceutical care, pharmacy care, and good pharmacy practice
- Beneficial effects of rutin, quercitrin and quercetin on inflammatory bowel disease
- Use radionuclide x-ray fluorescence analysis for determination of heavy metals content in dextrans in solid and liquid state